Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update

被引：34
|
作者：
Giordano, Sharon H. [1 ]
Freedman, Rachel A. [2 ]
Somerfield, Mark R. [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 03期
关键词：
D O I：
10.1200/JCO.21.02677
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.
引用
收藏
页码：307 / +
页数：4
相关论文
共 50 条
  • [31] Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
    Johnston, Stephen R. D.
    Harbeck, Nadia
    Hegg, Roberto
    Toi, Masakazu
    Martin, Miguel
    Shao, Zhi Min
    Zhang, Qing Yuan
    Martinez Rodriguez, Jorge Luis
    Campone, Mario
    Hamilton, Erika
    Sohn, Joohyuk
    Guarneri, Valentina
    Okada, Morihito
    Boyle, Frances
    Neven, Patrick
    Cortes, Javier
    Huober, Jens
    Wardley, Andrew
    Tolaney, Sara M.
    Cicin, Irfan
    Smith, Ian C.
    Frenzel, Martin
    Headley, Desiree
    Wei, Ran
    San Antonio, Belen
    Hulstijn, Maarten
    Cox, Joanne
    O'Shaughnessy, Joyce
    Rastogi, Priya
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34) : 3987 - 3998
  • [32] Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
    Rugo, H. S.
    O'Shaughnessy, J.
    Boyle, F.
    Toi, M.
    Broom, R.
    Blancas, I
    Gumus, M.
    Yamashita, T.
    Im, Y-H
    Rastogi, P.
    Zagouri, F.
    Song, C.
    Campone, M.
    San Antonio, B.
    Shahir, A.
    Hulstijn, M.
    Brown, J.
    Zimmermann, A.
    Wei, R.
    Johnston, S. R. D.
    Reinisch, M.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2022, 33 (06) : 616 - 627
  • [33] Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
    Burstein, Harold J.
    Lacchetti, Christina
    Griggs, Jennifer J.
    JOURNAL OF ONCOLOGY PRACTICE, 2019, 15 (02) : 106 - +
  • [34] Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
    Burstein, Harold J.
    Lacchetti, Christina
    Anderson, Holly
    Buchholz, Thomas A.
    Davidson, Nancy E.
    Gelmon, Karen A.
    Giordano, Sharon H.
    Hudis, Clifford A.
    Solky, Alexander J.
    Stearns, Vered
    Winer, Eric P.
    Griggs, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (05) : 423 - +
  • [35] Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
    Fleming, G. F.
    Pagani, O.
    Regan, M. M.
    Walley, B. A.
    Francis, P. A.
    ANNALS OF ONCOLOGY, 2022, 33 (06) : 658 - 658
  • [36] Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update (vol 40, pg 1816, 2022)
    Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (22) : 2514 - 2514
  • [37] Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
    Harbeck, N.
    Rastogi, P.
    Martin, M.
    Tolaney, S. M.
    Shao, Z. M.
    Fasching, P. A.
    Huang, C. S.
    Jaliffe, G. G.
    Tryakin, A.
    Goetz, M. P.
    Rugo, H. S.
    Senkus, E.
    Testa, L.
    Andersson, M.
    Tamura, K.
    Del Mastro, L.
    Steger, G. G.
    Kreipe, H.
    Hegg, R.
    Sohn, J.
    Guarneri, V
    Cortes, J.
    Hamilton, E.
    Andre, V
    Wei, R.
    Barriga, S.
    Sherwood, S.
    Forrester, T.
    Munoz, M.
    Shahir, A.
    San Antonio, B.
    Nabinger, S. C.
    Toi, M.
    Johnston, S. R. D.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2021, 32 (12) : 1571 - 1581
  • [38] Primary Outcome Analysis of Invasive Disease-Free Survival for MonarchE: Abemaciclib Combined With Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
    O'Shaughnessy, Joyce A.
    Johnston, Stephen
    Harbeck, Nadia
    Toi, Masakazu
    Im, Young-Hyuck
    Reinisch, Mattea
    Shao, Zhimin
    Lehtinen, Pirkko Liisa Kellokumpu
    Huang, Chiun-Sheng
    Tryakin, Alexey
    Goetz, Matthew
    Rugo, Hope S.
    Senkus, Elzbieta
    Testa, Laura
    Andersson, Michael
    Tamura, Kenji
    Steger, Guenther G.
    Del Mastro, Lucia
    Cox, Joanne
    Forrester, Tammy
    Sherwood, Sarah
    Li, Xuelin
    Wei, Ran
    Martin, Miguel
    Rastogi, Priya
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 15 - 16
  • [39] Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update
    Moy, Beverly
    Rumble, Bryan
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (26) : 3088 - +
  • [40] Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment
    Naoki Niikura
    Morihiko Kimura
    Takayuki Iwamoto
    Naoki Hayashi
    Junichi Shintoku
    Yuki Saito
    Yasuhiro Suzuki
    Yutaka Tokuda
    Breast Cancer, 2013, 20 : 67 - 74
12345